A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Stopped Trial terminated because of lack of efficacy in the short term acute phase.

Conditions

• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes

Interventions

• DRUG: CC-90009

Sponsor

Celgene